Filter Results:
(624)
Show Results For
- All HBS Web
(624)
- People (2)
- News (57)
- Research (449)
- Events (2)
- Multimedia (8)
- Faculty Publications (395)
Show Results For
- All HBS Web
(624)
- People (2)
- News (57)
- Research (449)
- Events (2)
- Multimedia (8)
- Faculty Publications (395)
- September 2009 (Revised December 2009)
- Supplement
Genzyme Center (B)
By: Michael W. Toffel and Aldo Sesia
Genzyme Corporation is in the midst of planning its new corporate headquarters, which incorporates many innovative green building features. After learning that the building as planned would likely earn a LEED Silver rating, an intermediate score in the LEED green... View Details
Keywords: Environmental Sustainability; Corporate Social Responsibility and Impact; Standards; Cost vs Benefits; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry
Toffel, Michael W., and Aldo Sesia. "Genzyme Center (B)." Harvard Business School Supplement 610-009, September 2009. (Revised December 2009.)
- 09 Apr 2012
- Research & Ideas
Who Sways the USDA on GMO Approvals?
Many corporations have gotten good at pulling the levers of government to tilt the odds in their favor, weakening regulations or securing perks, justified or not, to further their business interests. Economists use the term "regulatory capture" to describe... View Details
- September 2013 (Revised August 2014)
- Case
Claritas Genomics
By: Robert F. Higgins and Matthew Preble
Claritas Genomics was formed in January 2013 when BCH spun out its Genetics Diagnostic Lab into a fully commercial entity. Claritas offered over 100 genomic tests to detect a range of conditions, including autism and intellectual disabilities, and was developing new... View Details
Keywords: Boston Children's Hospital; Genetic Engineering; Genetically Modified; Genetics Diagnostics; Health Care Industry; Healthcare IT; Healthcare Technology; Healthcare Ventures; Biomedical Research; Patrice Milos; Genomics; Genomic Testing; Life Technologies; Health Care and Treatment; Information Technology; Information Management; Genetics; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Boston; Massachusetts; United States
Higgins, Robert F., and Matthew Preble. "Claritas Genomics." Harvard Business School Case 814-032, September 2013. (Revised August 2014.)
- September 2008
- Background Note
Background on the Technology of Molecular Diagnostics
By: Regina E. Herzlinger and Jason Sanders
To be used as background reading for the "EXACT Sciences Corp.: Commercializing a Diagnostic Test" and "Diagnostic Genomics" cases, HBS nos. 308-090 and 309-040. View Details
Herzlinger, Regina E., and Jason Sanders. "Background on the Technology of Molecular Diagnostics." Harvard Business School Background Note 309-050, September 2008.
- Web
Dean Srikant Datar’s 2023 Commencement Remarks | About
join the biotechnology firm Vertex, where she led teams to make innovative medicines that treat chronic diseases like cystic fibrosis. Amid a busy career, Depelsha McGruder acted courageously to launch Moms of Black Boys United to... View Details
- March 2014
- Module Note
Implementing Environmentally Sustainable Operations
Keywords: Sustainability; Sustainability Management; Sustainability Reporting; Sustainable Supply Chains; Sustainable Operations; Environment; Environmental And Social Sustainability; Environmental Management; Environmental Operations; Environmental Performance; Environmental Policy; Environmental Protection; Environmental Strategy; Environmental Regulation; Operations Management; Operations Strategy; Supply Chain Management; Operations; Supply Chain; Business Processes; Corporate Social Responsibility and Impact; Performance Evaluation; Performance Improvement; Safety; Social Enterprise; Quality; Production; Working Conditions; Animal-Based Agribusiness; Buildings and Facilities; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry
Toffel, Michael W. "Implementing Environmentally Sustainable Operations." Harvard Business School Module Note 613-090, March 2014.
- 23 Jun 2003
- Research & Ideas
Historically Speaking: A Roundtable at HBS
Pharmaceutical Industries, to be published by The Free Press in 2004]. It includes a chapter on biotechnology, the next industry that will create a sea change in our lives. Spar: And biotechnology will go through the same pattern of... View Details
Keywords: by Jim Aisner
- 01 Mar 2025
- News
Heartland
Let me tell you what’s fantastic about offal.” Jordan Kraft Lambert (MBA 2016), Colorado State University’s first director of agricultural innovation, is a full-body talker, and the topic of organ meat has her fired up. The parts of the cow typically seen as... View Details
- 01 Dec 2020
- News
In Review
Under his ten-and-one-half years of leadership, the School launched FIELD and HBS Online. It created two joint degree programs: an MS/MBA in Engineering in conjunction with the Paulson School of Engineering and Applied Sciences, and an MS/MBA in Life Sciences & View Details
- March 2023
- Case
Moderna
By: Marco Iansiti, Karim R. Lakhani, Hannah Mayer, Kerry Herman, Allison J. Wigen and Dave Habeeb
This multimedia case follows the story of Moderna and its entry into vaccine development in the wake of the COVID-19 pandemic. In summer 2020, Stephane Bancel, CEO of biotech firm Moderna, faces several challenges as his company races to develop a vaccine for COVID-19.... View Details
- February 1986 (Revised November 1992)
- Case
Novo Industri A/S--1981
By: W. Carl Kester and Glynn Ferguson
This small but rapidly growing Danish biochemical company must choose among several financing opportunities that include a convertible Eurobond, a rights offering in Denmark and an issue of new common shares in the United States. The case involves a broad range of... View Details
Keywords: Capital Markets; Cost of Capital; Bonds; Stock Shares; Financing and Loans; Globalization; Biotechnology Industry; Biotechnology Industry; Denmark; United States
Kester, W. Carl, and Glynn Ferguson. "Novo Industri A/S--1981." Harvard Business School Case 286-084, February 1986. (Revised November 1992.)
- March 2022
- Teaching Note
Digital Manufacturing at Amgen
By: Shane Greenstein, Kyle R. Myers and Sarah Mehta
This teaching note provides guidance for instructors teaching “Digital Manufacturing at Amgen,” case no. 621-008. View Details
Keywords: Change; Change Management; Decision Making; Cost vs Benefits; Decisions; Information Technology; Analytics and Data Science; Innovation and Invention; Innovation and Management; Innovation Leadership; Innovation Strategy; Technological Innovation; Jobs and Positions; Knowledge; Leadership; Organizational Culture; Science; Strategy; Technology Adoption; Biotechnology Industry; Biotechnology Industry; United States; California; Puerto Rico; Rhode Island
- November 2020
- Supplement
Valuing Celgene's CVR
By: Benjamin C. Esty and Daniel Fisher
When Bristol-Myers Squibb (BMS) acquired Celgene Corporation in November 2019, Celgene shareholders received cash, BMS stock, and a contingent value right (CVRs) that would pay $9 if the U.S. Food and Drug Administration (FDA) approved three of Celgene’s late stage... View Details
- October 2019 (Revised April 2020)
- Background Note
Note on Funding Deep Tech Startups
By: Karim Lakhani, Peter Barrett and Noubar Afeyan
This Background Note provides essential information on funding deep technologies—those technologies that were inherently capital intensive, time consuming, risky, and potentially disruptive. Both dilutive and non-dilutive sources of investment are highlighted, along... View Details
Keywords: Entrepreneurship; Energy; Venture Capital; Corporate Finance; Initial Public Offering; Investment; Health Testing and Trials; Innovation and Invention; Technological Innovation; Intellectual Property; Product Design; Product Development; Information Technology; Research and Development; Risk and Uncertainty; Biotechnology Industry; Biotechnology Industry; United States; North America; Europe; Asia
Lakhani, Karim, Peter Barrett, and Noubar Afeyan. "Note on Funding Deep Tech Startups." Harvard Business School Background Note 620-029, October 2019. (Revised April 2020.)
- September 2019
- Case
Celgene: Business Development and Distributed Research
By: Peter Barrett and Kareem Reda
This case looks at the deal-making process between Celgene, a large publicly traded pharmaceutical company, and Agios, an early-stage biotech company. The framework of a potential deal is explored and the potential road-blocks to Agios’ profitability are discussed. ... View Details
Keywords: Negotiation Deal; Alliances; Collaborative Innovation and Invention; Research; Biotechnology Industry; Biotechnology Industry
Barrett, Peter, and Kareem Reda. "Celgene: Business Development and Distributed Research." Harvard Business School Case 620-014, September 2019.
- June 2014
- Supplement
Merrimack Pharmaceuticals, Inc. (B)
By: Amy C. Edmondson, Bethany Gerstein and Melissa Valentine
In 2006, the leadership team at Merrimack Pharmaceuticals, Inc. had to decide whether to keep its R&D organization in functional departments or restructure it into interdisciplinary teams. This case follows the outcomes of this decision from 2006 to mid-2014, and... View Details
Keywords: Organizational Design; Groups and Teams; Collaborative Innovation and Invention; Research and Development; Biotechnology Industry; Biotechnology Industry
Edmondson, Amy C., Bethany Gerstein, and Melissa Valentine. "Merrimack Pharmaceuticals, Inc. (B)." Harvard Business School Supplement 614-083, June 2014.
- April 2010
- Teaching Note
The DiagnoFirst Opportunity (TN)
By: Robert C. Pozen
Teaching Note for [309112]. View Details
- February 2010 (Revised April 2010)
- Case
Organization and Strategy at Millennium (A)
By: Julie M. Wulf and Scott Waggoner
This case examines Millennium's strategic and organizational responses to the rapid evolution of the biopharmaceutical industry. In the early 2000s, as Millennium's competitive advantage in early-stage research slipped away and its losses mounted, founder and CEO Mark... View Details
Keywords: Transformation; Leading Change; Management Succession; Organizational Change and Adaptation; Competitive Strategy; Competitive Advantage; Biotechnology Industry; Biotechnology Industry
Wulf, Julie M., and Scott Waggoner. "Organization and Strategy at Millennium (A)." Harvard Business School Case 710-415, February 2010. (Revised April 2010.)
- January 2009
- Teaching Note
Biocon: Launching a New Cancer Drug in India (TN)
By: Sunil Gupta and Das Narayandas
Teaching Note for [508026]. View Details
- August 2007 (Revised November 2008)
- Case
Biocon: Launching a New Cancer Drug in India
By: Sunil Gupta and Das Narayandas
Kiran Majumdar-Shaw, the CEO of Biocon has to make product launch timing, pricing, channel, and communications mix decisions relating to the launch of BioMAb, a new cancer drug in India. View Details
Keywords: Price; Health Care and Treatment; Marketing Strategy; Product Launch; Planning; Biotechnology Industry; Biotechnology Industry; India
Gupta, Sunil, and Das Narayandas. "Biocon: Launching a New Cancer Drug in India." Harvard Business School Case 508-026, August 2007. (Revised November 2008.)